Latest Regulatory News

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

Resouro Strategic Metals has amended its private placement terms, aiming to raise CAD 3 million to fund engineering work for its Tiros Titanium-Rare Earths Project in Brazil.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Ballard Mining reports strong infill drilling results at its Baldock gold deposit, confirming and refining a high-grade resource and targeting a maiden reserve by mid-2026. The ongoing program highlights potential resource growth beyond current estimates.

Locksley Resources reports robust metallurgical testwork from its Mojave Project, confirming high antimony recoveries and concentrate grades that support a domestic US supply chain. The results align with US strategic priorities for critical mineral independence.

Brightstar Resources has obtained key regulatory approvals for its Lord Byron open pit project, positioning the company to commence mining operations in the second half of 2026. This milestone advances Brightstar’s strategy to boost gold production from its Laverton Hub.

Vault Minerals projects steady gold production in FY26 with growth through FY28, driven by key plant upgrades and the anticipated restart of Sugar Zone operations. The company plans significant capital and exploration investments while preparing to fully unwind its hedge book.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

Peak Rare Earths Limited shares have been suspended from the ASX following court approval of a scheme of arrangement for acquisition by Shenghe Resources. The suspension precedes the expected delisting later this month.

Everlast Minerals Ltd has issued a Replacement Prospectus for a $4-6 million ASX IPO to fund its mineral sands projects in Bangladesh, focusing on advancing the Gaibandha project towards commercial production.